FibroScan分别与GPR、APRI、NFS、FIB-4联合应用对慢性乙型肝炎合并非酒精性脂肪性肝病进展期肝纤维化的诊断价值比较

龚航; 李良平

doi:10.3969/j.issn.1001-5256.2020.03.014

FibroScan分别与GPR、APRI、NFS、FIB-4联合应用对慢性乙型肝炎合并非酒精性脂肪性肝病进展期肝纤维化的诊断价值比较

DOI: 10.3969/j.issn.1001-5256.2020.03.014

龚航,
李良平

1. 自贡市第一人民医院消化内科
2. 四川省医学科学院·四川省人民医院消化内科

基金项目:

四川省卫计委重点课题(16ZD024)；

详细信息

中图分类号: R512.62;R575.5
计量
- 文章访问数: 1846
- HTML全文浏览量: 72
- PDF下载量: 278
- 被引次数: 32
出版历程
- 出版日期: 2020-03-20

Value of Fibroscan combined with GPR,APRI,NFS or FIB-4 for progressive liver fibrosis in patients with chronic hepatitis B and nonalcoholic fatty liver disease

Department of Gastroenterology, The First People’s Hospital of Zigong

Research funding:

摘要

摘要: 目的评价FibroScan、GPR、APRI、NFS、FIB-4单独应用及FibroScan分别与GPR、APRI、NFS、FIB-4联合应用对慢性乙型肝炎（CHB）合并非酒精性脂肪性肝病（NAFLD）患者进展期肝纤维化的诊断价值。方法选取2014年11月-2018年8月在四川省人民医院行肝穿刺病理检查并确诊为CHB合并NAFLD的患者92例。根据肝穿刺病理SAF分级诊断标准,分为轻中度肝纤维化（F1+F2）组（n=69）和进展期肝纤维化（F3）组（n=23）。同时应用FibroScan测得肝脏硬度值,根据临床指标分别计算GPR、APRI、NFS、FIB-4。计量资料两组间比较采用Mann-Whitney U检验;相关性分析采用Spearman秩相关;多因素二元logistic回归构建联合预测因子（向前逐步回归法）,绘制受试者工作特征曲线（ROC曲线）,计算ROC曲线下面积（AUC）,并采用Delong方法进行比较,评价各种无创诊断方法单独及联合应用对CHB合并NAFLD进展期肝纤维化的诊断价值。结果轻中度肝纤维化组的FibroScan、GPR、APRI、NFS及FIB-4水平明显低于...
- 乙型肝炎,慢性 /
- 非酒精性脂肪性肝病 /
- 肝硬化 /
- 诊断
Abstract: Objective To investigate the diagnostic value of FibroScan,gamma-glutamyl transpeptidase-to-platelet ratio( GPR),aspartate aminotransferase-to-platelet ratio index( APRI),nonalcoholic fatty liver disease( NAFLD) fibrosis score( NFS),and fibrosis-4( FIB-4) used alone or FibroScan combined with GPR,APRI,NFS,or FIB-4 for progressive liver fibrosis in patients with chronic hepatitis B( CHB) and NAFLD. Methods A total of 92 patients who underwent liver biopsy in Sichuan Provincial People's Hospital from November 2014 to August 2018 and were diagnosed with CHB and NAFLD were enrolled. Based on the SAF scoring system for liver biopsy,these patients were divided into mild-to-moderate liver fibrosis( F1 + F2) group with 69 patients and progressive liver fibrosis( F3) group with 23 patients. FibroScan was used to obtain liver stiffness measurement( LSM),and GPR,APRI,NFS,and FIB-4 were calculated based on clinical indices. The Mann-Whitney U test was used for comparison of continuous data between two groups. Spearman rank correlation was used for correlation analysis. A multivariate binary logistic regression analysis( forward stepwise regression) was used to construct combined predictive factors. The receiver operating characteristic( ROC) curve was plotted,and the area under the ROC curve( AUC) was calculated,and Delong method was used to compare the AUC to evaluate the early-warning value of each noninvasive diagnostic method used alone or in combination in the diagnosis of CHB and progressive liver fibrosis. Results The mild-to-moderate liver fibrosis group had significantly lower values of FibroScan,GPR,APRI,NFS,and FIB-4 than the progressive liver fibrosis group( Z =-4. 910,-3. 425,-3. 837,-3. 873,and-3. 990,all P < 0. 05). The correlation analysis showed that FibroScan,GPR,APRI,NFS,and FIB-4 were positively correlated with the pathological staging of liver fibrosis( r = 0. 518,0. 361,0. 405,0. 407,and 0. 418,P < 0. 05). FibroScan,GPR,APRI,NFS,and FIB-4 used alone had a certain clinical value in the diagnosis of progressive liver fibrosis( AUC = 0. 844,0. 740,0. 770,0. 771,and 0. 779,all P < 0. 001),while FibroScan was not superior to GPR,APRI,NFS,and FIB-4( P > 0. 05). FibroScan combined with GPR,APRI,NFS,or FIB-4 had a significantly higher AUC than GPR,APRI,NFS,or FIB-4 used alone in the diagnosis of progressive liver fibrosis( Z = 1. 977,2. 076,2. 361,and 2. 206,all P < 0. 05). FibroScan combined with these four indices had an AUC of 0. 896( 95% confidence interval: 0. 813-0. 950). Conclusion FibroScan,GPR,APRI,NFS,and FIB-4 have a certain clinical value in the diagnosis of progressive liver fibrosis,and FibroScan combined with GPR,APRI,NFS,or FIB-4 has higher efficiency than GPR,APRI,NFS,or FIB-4 used alone in the diagnosis of progressive liver fibrosis,among which FibroScan combined with NFS or FIB-4 may have the best clinical value.
- hepatitis B,chronic /
- non-alcoholic fatty liver disease /
- liver cirrhosis /
- diagnosis

HTML全文

参考文献(16)

[1] WONG VW,WONG GL,CHU WC,et al. Hepatitis B virus infection and fatty liver in the general population[J]. J Hepatol,2012,56(3):533-540.

[2] ZHU L,JIANG J,ZHAI X,et al. Hepatitis B virus infection and risk of non-alcoholic fatty liver disease:A population-based cohort study[J]. Liver Int,2019,39(1):70-80.

[3] YANG RX,FAN JG. Characteristics,diagnosis and management of concomitant fatty liver in hepatitis B patients[J]. Chin J Clin Infect Dis,2018,11(3):174-178.(in Chinese)杨蕊旭，范建高．乙型肝炎合并脂肪肝的特征和诊治对策[J]．中华临床感染病杂志，2018,11(3):174-178.

[4] WILDER J,PATEL K. The clinical utility of FibroScanas a noninvasive diagnostic test for liver disease[J]. Med Devices(Auckl),2014,7:107-114.

[5] LU XJ,LI XH,YUAN ZX,et al. Assessment of liver fibrosis with the gamma-glutamyl transpeptidase to platelet ratio:A multicentre validation in patients with HBV infection[J]. Gut,2018,67(10):1903-1904.

[6] ZHANG DK,CHEN M,LIU Y,et al. The diagnostic value of ARFI imaging and APRI for quantitative evaluating the degree of liver fibrosis in NAFLD patients[J]. J Chin Clin Med Imaging,2013,24(3):178-181,187.(in Chinese)张大鹍，陈敏，刘阳，等．ARFI与APRI指数对非酒精性脂肪性肝病肝纤维化的诊断价值[J]．中国临床医学影像杂志，2013,24(3):178-181,187.

[7] SUN W,CUI H,LI N,et al. Comparison of FIB-4 index,NAFLD fibrosis score and BARD score for prediction of advanced fibrosis in adult patients with non-alcoholic fatty liver disease:A meta-analysis study[J]. Hepatol Res,2016,46(9):862-870.

[8] CHALASANI N,YOUNOSSI Z,LAVINE JE,et al. The diagnosis and management of nonalcoholic fatty liver disease:Practice guidance from the American Association for the Study of Liver Diseases[J]. Hepatology,2018,67(1):328-357.

[9] National Workshop on Fatty Liver and Alcoholic Liver Disease,Chinese Society of Hepatology,Chinese Medical Association;Fatty Liver Expert Committee,Chinese Medical Doctor Association. Guidelines of prevention and treatment for nonalcoholic fatty liver disease:A 2018 update[J]. J Clin Hepatol,2018,34(5):947-957.(in Chinese)中华医学会肝病学分会脂肪肝和酒精性肝病学组，中国医师协会脂肪性肝病专家委员会．非酒精性脂肪性肝病防治指南(2018年更新版)[J]．临床肝胆病杂志，2018,34(5):947-957.

[10] Chinese Society of Hepatology and Chinese Society of Infectious Diseases,Chinese Medical Association. The guideline of prevention and treatment for chronic hepatitis B:A 2015 update[J]. J Clin Hepatol,2015,31(12):1941-1960.(in Chinese)中华医学会肝病学分会，中华医学会感染病学分会．慢性乙型肝炎防治指南(2015年更新版)[J]．临床肝胆病杂志，2015,31(12):1941-1960.

[11] European Association for the Study of the Liver(EASL); European Association for the Study of Diabetes(EASD); European Association for the Study of Obesity(EASO). EASL-EASDEASO clinical practice guidelines for the management of nonalcoholic fatty liver disease[J]. J Hepatol,2016,64(6):1388-1402.

[12] KUMAR R,BOON-BEE GOH G. Chronic hepatitis B and fatty liver:Issues in clinical management[J]. Clin Res Hepatol Gastroenterol,2016,40(6):755-759.

[13] ZENG CM,LU SY,GUO TL,et al. The relationship between hepatic steatosis and chronic hepatitis B and the effects on liver fibrosis[J]. Int J Virol,2019,26(6):408-412.(in Chinese)曾钗明，卢世云，郭太林，等．肝脂肪变性与慢性乙型肝炎之间的关系及对肝纤维化的影响[J]．国际病毒学杂志，2019,26(6):408-412.

[14] WANG MM,WANG GS,SHEN F,et al. Hepatic steatosis is highly prevalent in hepatitis B patients and negatively associated with virological factors[J]. Dig Dig Sci,2014,59(10):2571-2579.

[15] LIANG J,LIU F,WANG F,et al. A noninvasive score model for prediction of NASH in patients with chronic hepatitis B and nonalcoholic fatty liver disease[J]. Biomed Res Int,2017,2017:8793278.

[16] XIAO G,ZHU S,XIAO X,et al. Comparison of laboratory tests,ultrasound,or magnetic resonance elastography to detect fibrosis in patients with nonalcoholic fatty liver disease:A meta-analysis[J]. Hepatology,2017,66(5):1486-1501.

施引文献

期刊类型引用(23)

1.	叶雅妹，周丽娜，杨文彦，孙芳，林勇，林春，潘晨. 无创方法诊断HBeAg阳性慢性乙型肝炎患者肝内炎症反应程度. 检验医学与临床. 2024(02): 237-241+246 . 百度学术
2.	吴彬彬，徐小琴，顾星星，解其华. 脂肪肝诊断中ElastPQ弹性成像技术检测肝硬度与肝纤维化评分及FIB-4指数的相关性分析. 肝脏. 2024(01): 73-76 . 百度学术
3.	刘成信. 血清学指标联合肝功能指标检验在脂肪肝诊断中的应用价值研究. 中国现代药物应用. 2024(08): 63-65 . 百度学术
4.	解洪立. HBV-DNA载量、GPR、AFP联合检验在乙型肝炎肝纤维化辅助诊断中的临床价值探析. 中华养生保健. 2024(20): 47-50 . 百度学术
5.	高颖惠，邓明月，朱瑞瑞，郭智贤，闫婧雅，赵雪萌，李志勤. 慢性乙型肝炎合并非酒精性脂肪性肝病患者无创肝纤维化模型的诊断评价及新模型的建立. 中华消化杂志. 2024(10): 686-692 . 百度学术
6.	许斌，孙龙. 肝硬度值联合S指数对乙型肝炎患者肝纤维化程度的诊断价值. 海南医学院学报. 2023(10): 746-750 . 百度学术
7.	张兆辉，庄轶超，杨文宪. 瞬时弹性成像技术对原发性胆汁性肝硬化、自身免疫性肝炎的鉴别及与肝脏纤维化程度、肝功能的相关性研究. 世界华人消化杂志. 2023(11): 464-469 . 百度学术
8.	石林丽，赵俊岭，刘鑫. GPR、FIB–4及AAR对自身免疫性肝病患者早期肝硬化的诊断价值. 深圳中西医结合杂志. 2023(12): 79-81+137 . 百度学术
9.	黄柏盛，区蓝芯，张莹洁，施梅姐，黎胜，萧焕明，池晓玲. 传统非侵入性纤维化模型对慢性乙型肝炎合并代谢相关脂肪性肝病发生显著肝纤维化的诊断价值. 临床肝胆病杂志. 2023(09): 2110-2116 . 本站查看
10.	丁艺文，操焕坤，宗方，张亚南. 二维超声剪切波弹性成像和血清学指标评分诊断慢性乙肝患者肝纤维化的价值. 浙江医学. 2023(18): 1937-1942 . 百度学术
11.	黎妮，黄裕林，马世河. 血Tim-3联合γ-GT/胆碱酯酶比值在转氨酶正常或轻度升高慢性乙型肝炎患者中的临床价值. 肝脏. 2022(01): 42-46 . 百度学术
12.	毛垚耀，何惠昌，谢露，刘光伟. 慢性乙型肝炎合并非酒精性脂肪性肝病患者临床特点研究进展. 现代消化及介入诊疗. 2022(02): 233-236 . 百度学术
13.	周家玲，王冰琼，孙亚朦，孟彤彤，武珊珊，马红，欧晓娟，尤红，贾继东，吴晓宁. LPRI评分在乙型肝炎肝纤维化及肝硬化中的诊断价值. 临床肝胆病杂志. 2022(07): 1529-1533 . 本站查看
14.	杜乔慧，吴克俭，王争争. GP73、GPR对慢性乙型肝炎患者肝硬化的诊断价值. 胃肠病学和肝病学杂志. 2022(07): 758-763 . 百度学术
15.	蒋艳明，刘静，尤宁宁，王洁，陈公英，潘孝本，施军平. 血清无创方法诊断慢性乙型肝炎病毒感染者肝纤维化的效果评价. 国际流行病学传染病学杂志. 2022(04): 238-241 . 百度学术
16.	郭金伟. 慢性乙肝患者肝纤维化严重程度与血清TGF-β的相关性分析. 系统医学. 2022(23): 15-19 . 百度学术
17.	陈兴，梁小桃. 肝瞬时弹性成像与天冬氨酸转氨酶/血小板指数在慢性乙型肝炎合并脂肪肝患者肝纤维化诊断中的应用价值. 中国当代医药. 2021(11): 60-62 . 百度学术
18.	李广平，张红心，张蕾，周鹏翔，王亚囡. 透明质酸、Ⅳ型胶原、APRI及纤维蛋白原-4对乙型肝炎后肝纤维化的诊断价值. 临床和实验医学杂志. 2021(13): 1385-1388 . 百度学术
19.	周新兰，王雁冰，陆伟，李秀芳，黄丹，张占卿，丁荣蓉. 5种血清无创模型对慢性乙型肝炎肝纤维化分期诊断价值的比较. 临床肝胆病杂志. 2021(07): 1567-1571 . 本站查看
20.	何雨倩，马德强，曾伊凡，王传敏，陈悦. 无创指标对肝静脉压力梯度及食管胃静脉曲张破裂出血的预测价值. 河南医学研究. 2021(18): 3315-3319 . 百度学术
21.	音铭，李文庭. MicroRNA与肝纤维化相关的研究进展. 肝脏. 2021(08): 936-938 . 百度学术
22.	雷鸣. 恩替卡韦抗病毒对慢性乙型肝炎合并脂肪肝的效果分析. 中国现代药物应用. 2021(20): 168-170 . 百度学术
23.	何桥，原文聪，樊海宁，徐贺，任宾. 弹性成像联合血清学诊断慢性乙型肝炎肝纤维化的研究现状. 临床肝胆病杂志. 2021(12): 2914-2918 . 本站查看